Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2023年11月7日 - 8:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form 6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of November, 2023
Commission
File Number: 001-41106
Incannex
Healthcare Limited
(Exact
name of Registrant as specified in its charter)
not
applicable
(Translation
of Registrant’s name into English)
Australia
(Jurisdiction
of incorporation or organization)
Joel
Latham
Chief
Executive Officer and Managing Director
Level
39, Rialto South Tower
525 Collins Street
Melbourne
3000
Australia
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K
On
November 07, 2023, Incannex Healthcare Limited filed with the Australian Securities Exchange announcements captioned: “Change of
Director’s Interest x2”, a copy of which announcement is attached to this Form 6-K as Exhibit 99.1.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Incannex
Healthcare Limited |
|
|
|
Date:
November 07, 2023 |
By: |
/s/ Joel
Latham |
|
Name: |
Joel
Latham |
|
Title: |
Chief
Executive Officer and Managing Director |
INDEX
TO EXHIBITS
3
Exhibit 99.1
Appendix
3Y
Change
of Director’s Interest Notice
Rule
3.19A.2
Appendix
3Y
Change
of Director’s Interest Notice
Information
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property
and may be made public.
Introduced
30/09/01 Amended 01/01/11
Name of entity |
INCANNEX
HEALTHCARE LIMTIED |
ABN |
93 096 635 246 |
We
(the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section
205G of the Corporations Act.
Name
of Director |
Peter
Widdows |
Date
of last notice |
6
June 2023 |
Part
1 - Change of director’s relevant interests in securities
In
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note:
In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director”
should be disclosed in this part.
Direct
or indirect interest |
Direct
and indirect |
Nature
of indirect interest
(including
registered holder)
Note:
Provide details of the circumstances giving rise to the relevant interest. |
● The
Peter Widdows Superannuation Fund (Beneficiary)
● Wealthhub
Securities Noms P/L <JBWERE ACCUMULATION>
(Beneficiary) |
Date
of change |
31
October 2023 |
No.
and class of securities held prior to change |
DIRECT
● 15,973,694
IHL ordinary shares
● 1,064,913
unlisted $0.025 options expiring on 30 April 2026
INDIRECT
● 600,000
IHL ordinary shares
● 40,000
unlisted $0.025 options expiring on 30 April 2026 |
Number
acquired |
DIRECT
● 230,954
IHL ordinary shares
INDIRECT
● 280,000
IHL ordinary shares |
Number
disposed |
Nil |
Value/Consideration
Note:
If consideration is non-cash, provide details and estimated valuation
|
$33,842.10 |
+ See chapter 19 for defined terms. | |
| |
01/01/2011 Appendix 3Y Page 1 | |
Appendix
3Y
Change
of Director’s Interest Notice
No.
of securities held after change |
DIRECT
● 16,204,648
IHL ordinary shares
● 1,064,913
unlisted $0.025 options expiring on 30 April 2026
INDIRECT
● 880,000
IHL ordinary shares
● 40,000
unlisted $0.025 options expiring on 30 April 2026
|
Nature
of change
Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back |
On
Market Purchase |
Part
2 – Change of director’s interests in contracts
Note:
In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director”
should be disclosed in this part.
Detail
of contract |
N/A |
Nature
of interest |
|
Name
of registered holder
(if
issued securities)
|
|
Date
of change |
|
No.
and class of securities to which interest related prior to change
Note:
Details are only required for a contract in relation to which the interest has changed
|
|
Interest
acquired |
|
Interest
disposed |
|
Value/Consideration
Note:
If consideration is non-cash, provide details and an estimated valuation
|
|
Interest
after change |
|
Part
3 – +Closed period
Were
the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was
required? |
No. |
If
so, was prior written clearance provided to allow the trade to proceed during this period? |
|
If
prior written clearance was provided, on what date was this provided? |
|
+ See chapter 19 for defined terms. | |
| |
Appendix
3Y Page 2 | 01/01/2011 |
Appendix
3Y
Change of
Director’s Interest Notice
Rule 3.19A.2
Appendix
3Y
Change of Director’s Interest Notice
Information or documents not
available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be
made public.
Introduced
30/09/01 Amended 01/01/11
Name of entity |
INCANNEX HEALTHCARE LIMTIED |
ABN |
93 096 635 246 |
We (the entity) give ASX the
following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director |
Troy Valentine |
Date of last notice |
6 June 2023 |
Part 1 - Change
of director’s relevant interests in securities
In the case of a trust, this
includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company,
interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in
this part.
Direct
or indirect interest |
Direct
and indirect |
Nature
of indirect interest
(including
registered holder)
Note:
Provide details of the circumstances giving rise to the relevant interest.
|
See
notes below |
Date
of change |
3
November 2023 |
No.
and class of securities held prior to change |
●
36, 651 198 IHL Ordinary Shares
●
2,800,000
Options with various exercise prices, vesting dates and expiry dates.
●
2,443,413
unlisted $0.025 options expiring on 30 April 2026 |
Number
acquired |
●
11,091,950 IHL Ordinary Shares |
Number
disposed |
●
11,091,950 IHL Ordinary Shares |
Value/Consideration
Note:
If consideration is non-cash, provide details and estimated valuation |
$887,356
|
No.
of securities held after change |
●
36, 651 198 IHL Ordinary Shares
●
2,800,000
Options with various exercise prices, vesting dates and expiry dates.
●
2,443,413 unlisted $0.025 options expiring on 30 April 2026 |
+ See chapter 19 for defined terms. | |
| |
01/01/2011 Appendix 3Y Page 1 | |
Appendix 3Y
Change of
Director’s Interest Notice
Nature
of change
Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back |
Off
Market Transfer |
Part 2 –
Change of director’s interests in contracts
Note: In the case of a company,
interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in
this part.
Detail of contract |
N/A |
Nature of interest |
|
Name of registered holder
(if issued securities) |
|
Date of change |
|
No. and class of securities
to which interest related prior to change
Note: Details
are only required for a contract in relation to which the interest has changed |
|
Interest acquired |
|
Interest disposed |
|
Value/Consideration
Note: If consideration is non-cash, provide
details and an estimated valuation |
|
Interest after change |
|
Part 3 –
+Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? |
No. |
If so, was prior written clearance provided to allow the trade to proceed during this period? |
|
If prior written clearance was provided, on what date was this provided? |
|
+ See chapter 19 for defined terms. | |
| |
Appendix
3Y Page 2 | 01/01/2011 |
Appendix
3Y
Change of Director’s
Interest Notice
Notes –
Direct & Indirect Interests
(a) Description of entities/relationships:
| a. | A beneficiary of the GFCR Investments Trust, the FT Family Trust, and the Troy R Valentine Superfund; |
| b. | A director of Tranaj Nominees Pty Ltd, Valplan Pty Ltd, Alignment Capital Pty Ltd and Cityside Pty Ltd |
| c. | 100% shareholder in Cityside Pty Ltd (ACN 112 375 354)(“Cityside”) |
| d. | 50% shareholder in Alignment Capital Pty Ltd (ACN 167 124 754)(“Alignment”) |
2. | Ekirtson Nominees Pty Ltd (ACN 137 521 825) is trustee for the GFCR Investments Trust (“Ekirtson”) |
3. | Tranaj Nominees Pty Ltd (ACN 137 521 843) is trustee of the FT Family Trust (“Tranaj”) |
4. | Valplan Pty Ltd (ACCN 135 269 169) is trustee of the Troy R Valentine Family Superfund (“Valplan”) |
(b) Table 1 – holdings
before changes
|
IHL Ordinary Shares |
IHL Options |
Troy Valentine |
2,925,000^ |
2,800,000^^ |
Ekirtson * |
2,875,000 |
|
Tranaj * |
10,216,950 |
|
Valplan |
3,000,000 |
|
Alignment * |
13,194,248 |
|
Cityside |
4,440,000 |
|
TOTAL |
36,651,198 |
|
(c) Table 2 – holdings
after changes
|
IHL Ordinary Shares |
IHL Options |
Troy Valentine |
2,925,000^ |
2,994,999^^ |
Ekirtson * |
1,000,000 |
191,667 |
Tranaj * |
1,000,000 |
681,130 |
Valplan |
3,000,000 |
200,000 |
Alignment * |
24,286,198 |
879,617 |
Cityside |
4,440,000 |
296,000 |
TOTAL |
36,651,198 |
|
| * | Mr Valentine is not the sole beneficiary of these entities. |
| ^ | Of these 2,333,334 Securities issued to KMP as part of remuneration
package for FY 21 and 22, subsequent to Shareholder Approval obtained at the General Meeting of the Company on 09 June 2022; with vesting
dates as per details in the Notice of Meeting dated 12 May 2022. 466,666 Shares have already vested. |
| ^^ | Securities issued to KMP as part of remuneration package for
FY 21 and 22, subsequent to Shareholder Approval obtained at the General Meeting of the Company on 09 June 2022; with vesting dates as
per details in the Notice of Meeting dated 12 May 2022. |
+ See chapter 19 for defined terms. | |
| |
01/01/2011 Appendix 3Y Page 3 | |
Incannex Healthcare (PK) (USOTC:IHLXF)
過去 株価チャート
から 5 2024 まで 6 2024
Incannex Healthcare (PK) (USOTC:IHLXF)
過去 株価チャート
から 6 2023 まで 6 2024